July 11, 2019 - "Strong fundamentals fueling business development and pipeline progress"
JULY 11, 2019 – Zubsolv® remains the core driver of Orexo’s strong financial performance and record profitability. With a cash position of SEK 697 million and continued traction in the US, we remain focused on expanding our pipeline and product portfolio with commercially attractive assets to drive future growth.
JULY 10, 2019 – Today Orexo announces that an agreement have been signed for Zubsolv® in Australia and New Zealand with Mundipharma Australia, who has worked closely with Orexo in the approval process. Orexo will receive double-digit royalty on net sales and the launch in Australia will be initiated early next year.
Proud to have you within our partner network – congrats to your accomplishment taking this important project, OX-MP… https://t.co/SaKqGitUOc